newsfilter
← Latest News
GlobeNewswire·

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update

LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5%